Corline Biomedical AB (STO:CLBIO)

Sweden flag Sweden · Delayed Price · Currency is SEK
15.20
+0.10 (0.66%)
Mar 4, 2026, 12:16 PM CET
49.75%
Market Cap 389.33M
Revenue (ttm) 8.59M
Net Income (ttm) -14.71M
Shares Out 25.61M
EPS (ttm) -0.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 12,820
Average Volume 19,933
Open 15.20
Previous Close 15.10
Day's Range 14.50 - 15.20
52-Week Range 7.90 - 27.20
Beta 0.39
RSI 40.34
Earnings Date Feb 17, 2026

About Corline Biomedical AB

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company’s products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. Its products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1991
Employees 12
Stock Exchange Nasdaq Stockholm
Ticker Symbol CLBIO
Full Company Profile

Financial Performance

In 2025, Corline Biomedical AB's revenue was 8.59 million, a decrease of -50.29% compared to the previous year's 17.27 million. Losses were -14.71 million, -36.56% less than in 2024.

Financial Statements

News

There is no news available yet.